Abstract: Disclosed herein are system, method, and computer program product embodiments for detecting potentially unsafe wear levels in vehicle suspension systems. An embodiment operates by receiving acoustic signals of a vehicle suspension system, processing, the acoustic signals to generate training data, training a predictive learning algorithm to generate a predictive wear model and classifying the processed acoustic signals to indicate wear levels of one or more components of the vehicle suspension system. The trained predictive wear model subsequently predicts wear levels of the vehicle suspension system for notification to a cloud-based repository. Fleets of driverless vehicles may continuously monitor wear levels for timely maintenance before failure occurs.

Abstract: A latch assembly for an oven appliance is provided. The latch assembly allows for removable coupling of an oven accessory to a wall of a cabinet of the oven appliance. The latch assembly includes a latch body secured to the wall of the cabinet, a latch arm member, a pin, and a spring wire. The latch arm member has a pin movably engaged with and restricted by a path formed on a surface of the oven accessory. The spring wire engages with the latch arm member to limit movement of the pin within the path. Engaging the oven accessory with the latch assembly allows the pin to be secured within the path to secure the oven accessory to the wall of the cabinet. Re-engaging the oven accessory with the latch assembly allows for the oven accessory to release from the wall of the cabinet.

Abstract: Systems, methods, and computer-readable storage media for arranging a user interface based on account activity of a user are described herein. A method includes providing a user with access to online banking via a user device, providing a user interface on the user device including a plurality of display areas, and rearranging positions of the plurality of display areas of the user interface based on the user selecting an auto-arrange option. Selection of the auto-arrange option causes at least one of the plurality of display areas on the user interface to be arranged in a new position based on account activity of the user.

Abstract: Systems and methods for a multi-function mobility device to provide cargo container transport are provided. A multi-function mobility device includes a frame configurable between a plurality of configurations. The frame includes a plurality of individually controllable wheeled leg members configured to traverse uneven terrain. The mobility device is configured to transform the frame into a cargo transport configuration that accepts two stacks of cargo bins locked together. The mobility device is also configured to transform the frame into a rideable configuration that accepts a person.

Abstract: The present invention is directed to antibodies, including novel antigen binding domains and heterodimeric antibodies, that bind somatostatin receptor 2 (SSTR2).

Abstract: A semi-trailer including a cargo area, and an integrated fifth-wheel coupler unit extending horizontally along a front lower portion of the semi-trailer. The coupler unit includes an upper coupler surface defining a floor level of the cargo area, a lower coupler surface spaced below the upper coupler surface, and a kingpin projecting downwardly from the lower coupler surface and configured for coupling with a tow vehicle fifth wheel. A utility line connection portion is provided for establishing connections between at least one utility source of the tow vehicle and at least one utility component of the semi-trailer. The integrated fifth-wheel coupler unit includes a front wall with a recessed cavity at a central widthwise location accommodating the utility line connection portion.

Abstract: A mobile container chassis gooseneck straightener including a wheeled trailer. A frame structure of the straightener includes spaced top and bottom sections that receive a container chassis gooseneck. The frame structure includes a front end with a fixed column extending between the top and bottom sections. The frame structure includes a rear end comprising a removable link connecting the top and bottom sections. The removable link has a coupled state in which it rigidly secures the top and bottom sections and an uncoupled state in which the top and bottom sections are unsecured at the rear end. A hydraulic cylinder is supported by the frame structure and configured to exert vertical load on the container chassis gooseneck to be straightened within the frame structure. The frame structure is configured to bear the vertical load. A hydraulic power source is supported by the trailer and connected to power the hydraulic cylinder.

Abstract: A surgical visualization system comprises: (a) a set of one or more imaging devices, wherein the set of one or more imaging devices is adapted to capture a view of an interior of a cavity of a patient; (b) a display; and (c) a processor in operative communication with the set of one or more imaging devices and the display, wherein the processor is configured to present an interface on the display, the interface comprising a second field of view of the interior of the cavity of the patient, wherein the second field of view is comprised by the first field of view.

Abstract: The present invention is directed to binding molecules that possess one or more epitope-binding sites specific for an epitope of CD137 and one or more epitope-binding sites specific for an epitope of a tumor antigen (“TA”) (e.g., a “CD137×TA Binding Molecule”). In one embodiment, such CD137×TA Binding Molecules will be bispecific molecules, especially bispecific tetravalent diabodies, that are composed of two, three, four or more than four polypeptide chains and possessing two epitope-binding sites each specific for an epitope of CD137 and two epitope-binding sites each specific for an epitope of a TA. Alternatively, such CD137×TA Binding Molecules will be bispecific molecules, especially bispecific trivalent binding molecules composed of three or more polypeptide chains and possessing one or two epitope-binding sites each specific for an epitope of CD137 and one or two epitope-binding sites each specific for an epitope of a TA.

Abstract: The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Binding Domains may be selected such that the Tri-Specific Binding Molecules are capable of binding to any three different epitopes. Such epitopes may be epitopes of the same antigen or epitopes of two or three different antigens. In a preferred embodiment, one of such epitopes will be capable of binding to CD3, the second of such epitopes will be capable of binding to CD8, and the third of such epitopes will be capable of binding to an epitope of a Disease-Associated Antigen. The invention also provides a novel ROR1-binding antibody, as well as derivatives thereof and uses for such compositions.

Abstract: The present invention is directed to the anti-LAG-3 antibodies, LAG-3 mAb 1, LAG-3 mAb 2, LAG-3 mAb 4, LAG-3 mAb 5, and LAG-3 mAb 6, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to LAG-3-binding molecules that comprise LAG-3 binding fragments of such anti-LAG-3 antibodies, immunocongugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such LAG-3-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cells. The present invention also pertains to methods of detecting LAG-3, as well as methods of using molecules that bind LAG-3 for stimulating immune responses.

Abstract: The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Tri-Specific Binding Molecule is preferably characterized in possessing binding domains that permit it to immunospecifically bind to: (1) an epitope of a first Cancer Antigen, (2) an epitope of a second Cancer Antigen, and (3) an epitope of a molecule that is expressed on the surface of an immune system effector cell, and are thus capable of localizing an immune system effector cell to a cell that expresses a Cancer Antigen, so as to thereby facilitate the killing of such cancer cell.

Abstract: The present invention is directed to binding molecules that possess one or more epitope-binding sites specific for an epitope of CD137 and one or more epitope-binding sites specific for an epitope of a tumor antigen (“TA”) (e.g., a “CD137×TA Binding Molecule”). In one embodiment, such CD137×TA Binding Molecules will be bispecific molecules, especially bispecific tetravalent diabodies, that are composed of two, three, four or more than four polypeptide chains and possessing two epitope-binding sites each specific for an epitope of CD137 and two epitope-binding sites each specific for an epitope of a TA. Alternatively, such CD137×TA Binding Molecules will be bispecific molecules, especially bispecific trivalent binding molecules composed of three or more polypeptide chains and possessing one or two epitope-binding sites each specific for an epitope of CD137 and one or two epitope-binding sites each specific for an epitope of a TA.

Abstract: The present invention is directed to bispecific molecules (e.g., diabodies, bispecific antibodies, trivalent binding molecules, etc.) that possess at least one epitope-binding site that is immunospecific for an epitope of PD-1 and at least one epitope-binding site that is immunospecific for an epitope of CTLA-4 (i.e., a “PD-1×CTLA-4 bispecific molecule”). The PD-1×CTLA-4 bispecific molecules of the present invention are capable of simultaneously binding to PD-1 and to CTLA-4, particularly as such molecules are arrayed on the surfaces of human cells. The invention is directed to pharmaceutical compositions that contain such PD-1×CTLA-4 bispecific molecules, and to methods involving the use of such bispecific molecules in the treatment of cancer and other diseases and conditions. The present invention also pertains to methods of using such PD-1×CTLA-4 bispecific molecules to stimulate an immune response.

Abstract: The present invention is directed to DA×CD3 Binding Molecules comprising a vCD3-Binding Domain, which comprises a CDRH1 Domain, a CDRH2 Domain, a CDRH3 Domain, a CDRL1 Domain, a CDRL2 Domain, and a CDRL3 Domain, at least one of which differs in amino acid sequence from the amino acid sequence of the corresponding CDR of a rCD3-Binding Domain, wherein the DA×CD3 Binding Molecule comprising such vCD3-Binding Domain exhibits an altered affinity for CD3, relative to a DA×CD3 Binding Molecule comprising such rCD3-Binding Domain. The invention particularly concerns to such DA×CD3 Binding Molecules comprising a vCD3-Binding Domain which exhibit reduced affinity for CD3 and are capable of mediating redirected killing of target cells expressing a DA and exhibit lower levels of cytokine release relative to a DA×CD3 Binding Molecule comprising a rCD3-Binding Domain.

Abstract: The present invention is directed to the anti-LAG-3 antibodies: LAG-3 mAb 1, LAG-3 mAb 2, LAG-3 mAb 4, LAG-3 mAb 5, and LAG-3 mAb 6, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to LAG-3-binding molecules that comprise LAG-3 binding fragments of such anti-LAG-3 antibodies, immunoconjugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such LAG-3-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cell. The present invention also pertains to methods of detecting LAG-3, as well as methods of using molecules that bind LAG-3 for stimulating immune responses.

Abstract: CD19×CD3 bi-specific monovalent diabodies, and particularly, CD19×CD3 bi-specific monovalent Fc diabodies, are capable of simultaneous binding to CD19 and CD3, and are used in the treatment of hematologic malignancies.

Abstract: The present invention is directed to bispecific molecules (e.g., diabodies, bispecific antibodies, trivalent binding molecules, etc.) that possess at least one epitope-binding site that is immunospecific for an epitope of PD-1 and at least one epitope-binding site that is immunospecific for an epitope of CTLA-4 (i.e., a “PD-1×CTLA-4 bispecific molecule”). The PD-1×CTLA-4 bispecific molecules of the present invention are capable of simultaneously binding to PD-1 and to CTLA-4, particularly as such molecules are arrayed on the surfaces of human cells. The invention is directed to pharmaceutical compositions that contain such PD-1×CTLA-4 bispecific molecules, and to methods involving the use of such bispecific molecules in the treatment of cancer and other diseases and conditions. The present invention also pertains to methods of using such PD-1×CTLA-4 bispecific molecules to stimulate an immune response.

Abstract: A cargo body wall including one or more panels having interior and exterior sides. A plurality of primary logistics tracks are elongated in a first direction and have first and second portions spaced along the first direction with a hat-shaped profile in cross-section. The first and second portions include logistics fitting openings. The primary logistics tracks are secured to the one or more wall panels at the interior side such that the first and second portions project inward of an interior plane of the wall panel(s). A secondary logistics track is elongated in a second direction and has logistics fitting openings. The secondary logistics track is secured such that the first and second directions intersect and the secondary logistics track crosses each of the plurality of primary logistics tracks at a position between the first and second portions thereof.

Abstract: The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Binding Domains may be selected such that the Tri-Specific Binding Molecules are capable of binding to any three different epitopes. Such epitopes may be epitopes of the same antigen or epitopes of two or three different antigens. In a preferred embodiment, one of such epitopes will be capable of binding to CD3, the second of such epitopes will be capable of binding to CD8, and the third of such epitopes will be capable of binding to an epitope of a Disease-Associated Antigen. The invention also provides a novel ROR1-binding antibody, as well as derivatives thereof and uses for such compositions.